VGI Trugene Interpretation Software Showcased At Seville HIV/AIDS Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA's clearance process for future versions of Visible Genetics, Inc.'s HIV drug resistance assay interpretation systems may provide a key to how the agency will review next-generation genetic tests